Evoke Pharma Inc (EVOK) Latest Earnings Release Tops EPS By $0.07

Evoke Pharma Inc (EVOK) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. EVOK said it had a profit of $-0.12 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $-0.19. During the same quarter in the previous year, the company posted $-0.37 EPS.

Based on several research reports , Company shares were Reiterated by Rodman & Renshaw on Mar 16, 2017 to “Buy”, Firm has raised the Price Target to $ 9 from a previous price target of $6 .Laidlaw Upgraded Evoke Pharma Inc on Jan 30, 2017 to ” Buy”, Price Target of the shares are set at $8.Company shares were Upgraded by Rodman & Renshaw on Jan 5, 2017 to ” Buy”, Firm has raised the Price Target to $ 6 from a previous price target of $2.50 .Company shares were Reiterated by Rodman & Renshaw on Dec 23, 2016 to “Neutral”, Firm has raised the Price Target to $ 2.50 from a previous price target of $2 .

Several company insiders have filed Insider transactions , on Feb 24, 2017, Kenneth J Widder (director) purchased 450,000 shares at $2.90 per share price.

Evoke Pharma Inc opened for trading at $3.04 and hit $3.16 on the upside on Wednesday, eventually ending the session at $3.16, with a gain of 4.64% or 0.14 points. The heightened volatility saw the trading volume jump to 2,81,833 shares. Company has a market cap of $39 M.

Evoke Pharma Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001 a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate EVK-001 is in late stage clinical testing. EVK-001 is a formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal yielding a variety of symptoms.

Evoke Pharma Inc

Leave a Reply

Your email address will not be published. Required fields are marked *